Cantor outlines how to navigate the emerging Bitcoin treasury sector
Dennis Cho, Senior Vice President and Chief Legal Officer at Twist Bioscience Corp (NASDAQ:TWST), a $2.7 billion market cap biotechnology company, recently sold shares of the company’s common stock. According to InvestingPro data, TWST currently trades above its Fair Value, with the stock showing significant volatility in recent months. On March 20, Cho disposed of 230 shares at a price of $41.676 each, totaling approximately $9,585. This transaction was conducted to cover tax withholding obligations related to the vesting of Restricted Stock Units, as per the company’s equity incentive plans. Following this sale, Cho holds 111,662 shares of Twist Bioscience. The company maintains strong liquidity with a current ratio of 4.96 and operates with moderate debt levels, as revealed by InvestingPro’s comprehensive analysis, which includes 5 additional key insights about TWST’s financial health and market position.
In other recent news, Twist Bioscience Corporation reported financial results for the first quarter of fiscal year 2025 that exceeded consensus predictions and previous company guidance. The company revised its full-year fiscal 2025 guidance upwards, expecting total revenue growth of 19-21% year-over-year, with gross margins projected to be around 49% for the full year. Scotiabank (TSX:BNS) responded by raising its price target for Twist Bioscience to $62, maintaining a Sector Outperform rating. Meanwhile, Barclays (LON:BARC) also increased its price target to $58, reiterating an Overweight rating, citing growing momentum in the company’s Express portfolio and Next-Generation Sequencing tools.
Additionally, Twist Bioscience held its Annual Meeting of Stockholders, where stockholders approved an increase in authorized common stock by 100 million shares and amendments to the company’s equity incentive plan. The Charter was also amended to provide for the exculpation of certain officers from liability under specific circumstances. The company ended the first quarter with approximately $271 million in cash, a slight decrease from the previous quarter. Both Scotiabank and Barclays analysts expressed optimism about Twist Bioscience’s strategic focus and market potential, indicating positive expectations for the company’s future performance.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.